Pharmacogenomics and Toxicogenomics in Personalized Public Health: Integrating Genetic Insights, Emerging Technologies, and Global Regulatory Perspectives to Prevent Drug-Induced Toxicity and Enhance Therapeutic Outcomes

Background: Patient drug response, therapeutic outcomes, and the prevention of adverse reactions rely on pharmacogenomics and toxicogenomics, which study genetic variations influencing drug metabolism and toxicity. Integrating pharmacogenomics with toxicogenomics enhances patient safety by identifying individuals at risk of drug-induced toxicity and enables clinicians to make precise dose adjustments. Objectives: This research explores the implementation of pharmacogenomics and toxicogenomics in personalized medicine to assess their safety benefits, improvements in disease treatment, and potential to reduce healthcare costs. It also evaluates emerging technologies and discusses challenges associated with deploying these methodologies. Methods: A comprehensive analysis of genetic studies involving drug-metabolizing enzymes, receptors, and transport proteins was conducted. The evaluation focused on biomedical technologies, bioinformatics, and computational modeling to determine their ability to detect genomic indicators of drug toxicity. Additionally, this study examined how artificial intelligence (AI), machine learning (ML), and gene-editing technologies contribute to the advancement of personalized medical treatments. Results: Technological advancements have facilitated the discovery of genomic markers, improving drug toxicity prediction, regulatory assessment, and public health strategies. Integrating pharmacogenomic and toxicogenomic data into electronic medical records supports enhanced clinical decision-making and strengthens drug safety monitoring. However, widespread adoption remains limited due to ongoing ethical concerns, accessibility barriers, and regulatory inconsistencies. Conclusion: Collaboration among researchers, clinicians, industry stakeholders, and policymakers is essential to overcome implementation barriers to pharmacogenomic integration. The successful incorporation of pharmacogenomic and toxicogenomic data depends on expanding research foundations, enacting policy reforms, and developing educational initiatives to enhance patient safety and global healthcare outcomes.